For Immediate Release:
Contact: Kelly Broadway, 202-808-8853
[email protected]
Washington, D.C. – The Council for Affordable Health Coverage (CAHC) applauds Congressmen Brett Guthrie (R-KY), Jake Auchincloss (D-MA), John Joyce, M.D. (R-PA), Scott Peters (D-CA), Don Davis (D-NC), and Congresswoman Mariannette Miller-Meeks (R-IA) for reintroducing the Medicaid VBPs for Patients (MVP) Act, a bold step toward smarter drug spending and better patient outcomes.
A bipartisan bill backed by broad stakeholders, the MVP Act builds on the Centers for Medicare & Medicaid Services’ rule and recent Trump administration activity, allowing public and private payers to voluntarily enter into value-based purchasing arrangements (VBPs) with drug manufacturers. VBPs tie reimbursement to a patient’s recovery instead of the amount of medication taken.
“This is a victory for both patients and the health care system,” said Sloane Salzburg, Vice President of the Council for Affordable Health Coverage. “The MVP Act paves the way for cutting-edge treatments, including gene therapies, to reach the people who need them most, particularly those living with rare diseases. Rather than relying on heavy-handed government price controls, this legislation offers a smarter, market-based approach by tying payments to outcomes – if the drug doesn’t work, you don’t pay.”
The MVP Act aims to make VBPs more accessible across federal and private insurance markets, paving the way for a more affordable, outcome-driven health care system.